Home > TREANDA for NHL > NHL Treatment > What is TREANDA?

What is TREANDA?

TREANDA is a unique chemotherapy that has been shown to kill cells that cause indolent B-cell non-Hodgkin’s lymphoma (NHL). The exact way that TREANDA kills cells is still being studied in labs.

In a clinical study, 100 patients received TREANDA without it being combined with another drug. The study included patients who were diagnosed with a form of indolent B-cell NHL and who had received prior treatment with rituximab or a rituximab-containing regimen and whose disease progressed during or within 6 months of treatment.

Seventy-four percent of patients showed an overall response (this includes patients who showed a complete response or partial response) when TREANDA was used alone in patients with indolent B-cell NHL. High response rates were also seen even in patients who had failed treatment with 2 previous therapies.

How will I receive TREANDA?

You will get TREANDA either at your doctor’s office, the hospital, or at an infusion center. You will be given TREANDA as an intravenous (IV) infusion. This means that TREANDA will be given through a needle in your vein for 60 minutes. After treatment is finished, you can leave. TREANDA may be given for up to 8 cycles. Each cycle is made up of 21 days. You will be given TREANDA on Day 1 and Day 2 of each 21-day cycle.

As explained earlier, not all patients are the same, so it may be necessary for your doctor to make changes to the dose of TREANDA to find out what is right for you. Changing the dose or delaying treatment may be necessary if you are experiencing side effects.

> Next page: What to Expect

Indications

TREANDA is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL). Efficacy relative to first-line therapies other than chlorambucil has not been established.

TREANDA is indicated for the treatment of patients with indolent B-cell non-Hodgkin’s lymphoma (NHL) that has progressed during or within 6 months of treatment with rituximab or a rituximab-containing regimen.

Important Safety Information

  • The most common non-blood-related side effects (occurring in ≥15% of patients) with TREANDA are nausea, fatigue, vomiting, diarrhea, pyrexia (fever), constipation, anorexia (loss of appetite), cough, headache, weight decreased, dyspnea (difficulty breathing), rash, and stomatitis (inflammation of the mouth)
  • The most common blood-related side effects (occurring in ≥15% of patients) with TREANDA are reduction of lymphoid cells in the blood, low counts of leukocytes (white blood cells), reduction of red blood cells, reduction of neutrophils (white blood cells) and reduction of blood platelets
  • Allergic Reactions: There is a possibility of mild or serious allergic reactions with TREANDA. Immediately report rash, facial swelling, or difficulty breathing during or soon after infusion because these symptoms may become severe or even life-threatening
  • Myelosuppression: TREANDA may cause a decrease in white blood cells, platelets, and red blood cells. You will need frequent monitoring of your blood cells. Report shortness of breath, significant fatigue, bleeding, fever, or other signs of infection because these symptoms may become severe or even life-threatening
  • Pregnancy and Nursing: TREANDA can cause fetal harm. Women should avoid becoming pregnant throughout treatment and for 3 months after TREANDA therapy has stopped. Men receiving TREANDA should use reliable contraception for the same time period. Report pregnancy immediately. Avoid nursing while receiving TREANDA
  • Fatigue: TREANDA may cause tiredness. Avoid driving any vehicle or operating any dangerous tools or machinery if you experience this side effect
  • Nausea and Vomiting: TREANDA may cause nausea and/or vomiting. You should report nausea and vomiting to your doctor so that you can get treatment for these symptoms
  • Diarrhea: TREANDA may cause diarrhea. You should report diarrhea to your doctor so that it can be treated
  • Rash: A mild rash or itching may occur during treatment with TREANDA. Immediately report severe or worsening rash or itching to your doctor
  • Some side effects may lead to the dose of TREANDA being lowered, stopped, or delayed
  • You should not take TREANDA if you have a known allergy to bendamustine or mannitol

Here's your chance to share your story. Enroll Today!

right arrow